Infinity Pharma (INFI) Misses Q1 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Infinity Pharmaceutical (INFI) PT Cut to $13 at Nomura Securities
May 7, 2015 9:46 AM EDTNomura Securities analyst M. Ian Somaiya lowered its price target on Infinity Pharmaceutical (NASDAQ: INFI) to $13.00 (from $17.00) while reiterating a Neutral rating.
Somaiya commented, "We believe Infinity is building a comprehensive development plan for duvelisib, following its strategic partnership with AbbVie... More
Deutsche Bank Starts Infinity Pharmaceutical (INFI) at Buy
May 7, 2015 6:57 AM EDTDeutsche Bank initiated coverage on Infinity Pharmaceutical (NASDAQ: INFI) with a Buy rating and a price target of $20.00. Analyst Robyn Karnauskas sees a place for Duvelisib in the iNHL &and CL markets.
"Infinity is developing Duvelisib in various blood cancers. We... More
